SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
biotech firesales
An SI Board Since August 2001
Posts SubjectMarks Bans
3661 167 0
Emcee:  dalroi Type:  Moderated
Introduction Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
3536My granddad had Parkinson's psychosis, and had to be separated from his wifetuck-4/9/2018
3535My mother had LBD and struggled with it for years before succumbing in her late semi_infinite -4/9/2018
3534Acadia (ACAD) off ~20% on negative article about Nuplazid, suggesting label expatuck-4/9/2018
3533MNLO down more than 50% on trial failureJamesK-4/9/2018
3532MannKind (MNKD) off 21% on stock offering. Now well below $2. Not a buying op,tuck-4/6/2018
3531Incyte (INCY) of 20% from already depressed prices on failure of ECHO-301, a P3 tuck-4/6/2018
3530They are "warrants", without obligation. Still, positive for GLMD.Miljenko Zuanic-4/4/2018
3529Astonishingly good terms for GLMD. Warrants very far out-of-the-money (3x pre-exDewDiligence_on_SI-4/3/2018
3528OT: finance.yahoo.com BVF see value in Aramchol!Miljenko Zuanic-4/3/2018
3527RIGL down 17% on fostamatinib fail in IgA nephropathy failmopgcw-4/3/2018
3526Edge Therapeutics (EDGE) off 88% as I type on P3 whiff in subarachnoid hemorrhatuck13/28/2018
3525Dose response curve does not fit, what dose will they used going forward????Miljenko Zuanic-3/19/2018
3524CDTX - 22% down. News release this morning that initially looked good sending thSteve Lokness-3/19/2018
3523Believing that he does not have data already? I am frustrated that there is delaMiljenko Zuanic-3/13/2018
3522What would be the point of promising data that they have no intention of deliverDewDiligence_on_SI-3/13/2018
3521And you believe him (GLMD CEO)? How many weeks one needs to do ALT/AST liver leMiljenko Zuanic13/13/2018
3520We may be in a better position to speculate on why ARRIVE failed when we see theDewDiligence_on_SI-3/13/2018
3519RE GLMD: Aramchol P2b (300, 600 mg, placebo) data from ARREST in June, MRI/MRS Miljenko Zuanic13/13/2018
3518Thanks for sharing. Always instructive to see a seasoned Biotech investor takinFiloF13/5/2018
3517Re: Dermira's lebrikizumab. Well, it's still in P2 for dose optimizatiotuck13/5/2018
3516I do not remember the name of the analyst that wrote a note on this. He was tryBiotech Jim-3/5/2018
3515RE:L ncbi.nlm.nih.gov <RESULTS:209 patients received study drug. At Week 12,Miljenko Zuanic13/5/2018
3514Tuck, were you surprised how far the stock was taken down today? As to the acneBiotech Jim13/5/2018
3513Dermira (DERM) off 65% on utter failure in P3 acne trials. High burn and early,tuck-3/5/2018
3512Akcea (AKCA) off 25% as volanesorsen continues to have issues with thrombocytopetuck-2/27/2018
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News